Crucell will receive $1.5M upfront and potentially $20M in milestones.
Talecris Biotherapeutics signed a second exclusive, commercial license agreement with Crucell for access to the PER.C6® cell line for the production of an undisclosed and specific protein.
Crucell will receive an upfront payment of $1.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $20 million.
The first deal was signed in September, also for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6 cell line. For that deal Crucell received an upfront payment of $2.5 million and is eligible for milestone payments of approximately $30 million across multiple indications.
